GnRH for Luteal Support in IVF/ICSI/FET Cycles

ConditionInfertility
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorUniversity Reproductive Associates

About this trial

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.

Disqualifiers

day 3 transfers

Trial design

Design model

Parallel

Treatments tested in this trial

  • GnRH

    Drug

    single shot of GnRH agonist

  • placebo

    Drug

    placebo

Treatment groups

350 Participants
are divided into 2 treatment groups
Group A: GnRH agonistExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Live birth per transfer

Time frame
9 months

Secondary outcomes

1

implantation rates

Time frame
4 weeks
2

clinical pregnancy

Time frame
4 weeks
3

rates of OHSS

Time frame
4 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.